Form 8-K - Current report:
SEC Accession No. 0001193125-22-311788
Filing Date
2022-12-23
Accepted
2022-12-23 16:11:02
Documents
14
Period of Report
2022-12-20
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d396766d8k.htm   iXBRL 8-K 31744
2 EX-99.1 d396766dex991.htm EX-99.1 10438
6 GRAPHIC g396766g1223120546524.jpg GRAPHIC 3209
  Complete submission text file 0001193125-22-311788.txt   181384

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eq-20221220.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eq-20221220_lab.xml EX-101.LAB 19501
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eq-20221220_pre.xml EX-101.PRE 12157
8 EXTRACTED XBRL INSTANCE DOCUMENT d396766d8k_htm.xml XML 3577
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38692 | Film No.: 221485490
SIC: 2834 Pharmaceutical Preparations